Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

usana health sciences - USNA

USNA

Close Chg Chg %
18.10 0.28 1.55%

Pre-Market

18.38

+0.28 (1.55%)

Volume: 133.69K

Last Updated:

Apr 9, 2026, 3:59 PM EDT

Trade Now

Company Overview: usana health sciences - USNA

USNA Key Data

Open

$17.73

 Day Range

17.60 - 18.42

52 Week Range

16.60 - 38.32

 Market Cap

$333.52M

Shares Outstanding

18.46M

 Public Float

10.83M

Beta

0.70

 Rev. Per Employee

N/A

P/E Ratio

31.19

 EPS

$0.56

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

142.53K

  

USNA Performance

1 Week
 
 8.52%
 
1 Month
 
 5.77%
 
3 Months
 
 -7.61%
 
1 Year
 
 -25.87%
 
5 Years
 
 -81.64%
 

USNA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About usana health sciences - USNA

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

USNA At a Glance

USANA Health Sciences, Inc.
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
Phone 1-801-954-7100 Revenue 925.26M
Industry Pharmaceuticals: Other Net Income 10.76M
Sector Health Technology 2025 Sales Growth 8.28%
Fiscal Year-end 12 / 2026 Employees 1,570
View SEC Filings

USNA Valuation

P/E Current 31.193
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 33.558
Price to Sales Ratio 0.39
Price to Book Ratio 0.667
Price to Cash Flow Ratio 16.16
Enterprise Value to EBITDA 3.178
Enterprise Value to Sales 0.311
Total Debt to Enterprise Value 0.111

USNA Efficiency

Revenue/Employee 589,335.669
Income Per Employee 6,853.503
Receivables Turnover 101.621
Total Asset Turnover 1.241

USNA Liquidity

Current Ratio 2.236
Quick Ratio 1.438
Cash Ratio 1.232

USNA Profitability

Gross Margin 74.773
Operating Margin 5.497
Pretax Margin 4.488
Net Margin 1.163
Return on Assets 1.443
Return on Equity 1.922
Return on Total Capital 1.904
Return on Invested Capital 1.885

USNA Capital Structure

Total Debt to Total Equity 5.994
Total Debt to Total Capital 5.655
Total Debt to Total Assets 4.301
Long-Term Debt to Equity 2.308
Long-Term Debt to Total Capital 2.178
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Usana Health Sciences - USNA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
998.60M 921.01M 854.50M 925.26M
Sales Growth
-15.83% -7.77% -7.22% +8.28%
Cost of Goods Sold (COGS) incl D&A
207.28M 189.40M 175.75M 233.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
21.41M 20.39M 22.23M 39.70M
Depreciation
19.69M 18.56M 20.71M 20.38M
Amortization of Intangibles
1.72M 1.83M 1.52M 19.32M
COGS Growth
-10.24% -8.63% -7.20% +32.81%
Gross Income
791.32M 731.62M 678.75M 691.84M
Gross Income Growth
-17.19% -7.54% -7.23% +1.93%
Gross Profit Margin
+79.24% +79.44% +79.43% +74.77%
2022 2023 2024 2025 5-year trend
SG&A Expense
683.70M 638.54M 612.43M 640.98M
Research & Development
11.56M 11.45M 11.57M 10.69M
Other SG&A
672.14M 627.10M 600.86M 630.29M
SGA Growth
-12.94% -6.61% -4.09% +4.66%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 13.43M
-
EBIT after Unusual Expense
107.61M 93.07M 66.32M 37.43M
Non Operating Income/Expense
1.20M 9.64M 10.31M 4.94M
Non-Operating Interest Income
3.79M 9.64M 11.32M 2.42M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
192.00K 262.00K 281.00K 842.00K
Interest Expense Growth
+236.84% +36.46% +7.25% +199.64%
Gross Interest Expense
192.00K 262.00K 281.00K 842.00K
Interest Capitalized
- - - -
-
Pretax Income
108.62M 102.45M 76.35M 41.53M
Pretax Income Growth
-36.35% -5.68% -25.48% -45.61%
Pretax Margin
+10.88% +11.12% +8.94% +4.49%
Income Tax
39.27M 38.66M 34.29M 30.05M
Income Tax - Current - Domestic
339.00K 427.00K 330.00K 855.00K
Income Tax - Current - Foreign
45.87M 40.91M 40.70M 36.33M
Income Tax - Deferred - Domestic
(9.51M) (4.09M) (6.90M) (7.48M)
Income Tax - Deferred - Foreign
2.57M 1.42M 165.00K 345.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
69.35M 63.79M 42.06M 11.48M
Minority Interest Expense
- - 30.00K 717.00K
-
Net Income
69.35M 63.79M 42.03M 10.76M
Net Income Growth
-40.47% -8.02% -34.11% -74.40%
Net Margin Growth
+6.94% +6.93% +4.92% +1.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
69.35M 63.79M 42.03M 10.76M
Preferred Dividends
- - - -
-
Net Income Available to Common
69.35M 63.79M 42.03M 10.76M
EPS (Basic)
3.6018 3.3137 2.2002 0.5805
EPS (Basic) Growth
-37.72% -8.00% -33.60% -73.62%
Basic Shares Outstanding
19.25M 19.25M 19.10M 18.54M
EPS (Diluted)
3.5914 3.2974 2.1934 0.5793
EPS (Diluted) Growth
-37.29% -8.19% -33.48% -73.59%
Diluted Shares Outstanding
19.31M 19.34M 19.16M 18.57M
EBITDA
129.02M 113.47M 88.55M 90.56M
EBITDA Growth
-32.93% -12.06% -21.96% +2.27%
EBITDA Margin
+12.92% +12.32% +10.36% +9.79%

Snapshot

Average Recommendation HOLD Average Target Price 39.00
Number of Ratings 1 Current Quarters Estimate 0.45
FY Report Date 06 / 2026 Current Year's Estimate 2.00
Last Quarter’s Earnings 0.44 Median PE on CY Estimate N/A
Year Ago Earnings 1.93 Next Fiscal Year Estimate 2.77
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate 0.45 0.45 2.00 2.77
High Estimates 0.45 0.45 2.00 2.77
Low Estimate 0.45 0.45 2.00 2.77
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Usana Health Sciences - USNA

Date Name Shares Transaction Value
Mar 4, 2026 P. Joshua Foukas CHIEF LEGAL OFFICER 3,791 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 81,582.32
Mar 4, 2026 Paul A. Jones CHIEF PEOPLE OFFICER 12,374 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 266,288.48
Mar 4, 2026 Paul A. Jones CHIEF PEOPLE OFFICER 13,723 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Paul A. Jones CHIEF PEOPLE OFFICER 46,611 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Walter Noot CHIEF OPERATING OFFICER 12,400 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Walter Noot CHIEF OPERATING OFFICER 9,256 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 199,189.12
Mar 4, 2026 Brent Neidig CHIEF COMMERCIAL OFFICER 10,506 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Brent Neidig CHIEF COMMERCIAL OFFICER 7,513 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 161,679.76
Mar 4, 2026 Peter Benedict CHIEF INFORMATION OFFICER 38,602 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Peter Benedict CHIEF INFORMATION OFFICER 4,553 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 97,980.56
Mar 4, 2026 Peter Benedict CHIEF INFORMATION OFFICER 5,727 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 P. Joshua Foukas CHIEF LEGAL OFFICER 6,577 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Walter Noot CHIEF OPERATING OFFICER 75,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Kevin G. Guest CEO & EXEC. CHAIRMAN OF BOARD 127,206 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Kevin G. Guest CEO & EXEC. CHAIRMAN OF BOARD 45,381 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 976,599.12
Mar 4, 2026 Kevin G. Guest CEO & EXEC. CHAIRMAN OF BOARD 48,709 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 G. Doug Iiekking CHIEF FINANCIAL OFFICER 75,749 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 G. Doug Iiekking CHIEF FINANCIAL OFFICER 5,360 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.52 per share 115,347.20
Mar 4, 2026 G. Doug Iiekking CHIEF FINANCIAL OFFICER 10,391 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Brent Neidig CHIEF COMMERCIAL OFFICER 67,447 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Usana Health Sciences in the News